Cell proliferation as a long-term prognostic factor in diffuse large-cell lymphomas

✍ Scribed by Rosella Silvestrini; Aurora Costa; Patrizia Boracchi; Roberto Giardini; Franco Rilke

• Publisher: John Wiley and Sons
• Year: 1993
• Tongue: French
• Weight: 594 KB
• Volume: 54
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910540212

✦ Synopsis

The relevance of cell proliferation rate-defined as the 3H-thymidine labeling index CH-dT LI)-in predicting response to treatment (complete remission, CR), freedom from progression (FFP) and overall survival ( 0 s ) was evaluated in 86 patients with diffuse large-cell lymphoma (DLCL). The biologic variable was not associated with most of the established clinical factors, such as gender and age of the patient, performance status, 0 symptoms, tumor bulk, or extranodal disease, but was directly related to stage. 3H-dT LI significantly predicted short-and long-term clinical outcome. In fact, more patients with slowly proliferating DLCL reached CR and had longer median FFP and 0 s than patients with rapidly proliferating DLCL. Multipleregression analysis to evaluate the relative contribution of the different biologic and clinical variables in predicting CR, FFP and 0 s showed that 3H-dT LI and Ann Arbor stage were the only 2 stable factors, which retained their prognostic significance even in the presence of other conventional factors, and that 'H-dT LI was the most powerful as an indicator of risk of death in DLCL patients.